Astri Therapeutics Inc (ATXS) Stock Price, Quote & News

Latest News on ATXS

Apr 2, 2025, 4:10 PM EDT - 13 hours ago

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2025, 8:00 AM EDT - 22 days ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Feb 27, 2025, 8:00 AM EST - 4 weeks ago

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Feb 25, 2025, 8:00 AM EST - 5 weeks ago

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:00 AM EST - 5 weeks ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Feb 17, 2025, 10:32 PM EST - 6 weeks ago

Astria Therapeutics: A High-Conviction Bet On HAE

Feb 4, 2025, 8:00 AM EST - 2 months ago

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 2 months ago

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Jan 23, 2025, 8:00 AM EST - 2 months ago

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Jan 13, 2025, 8:00 AM EST - 2 months ago

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Dec 11, 2024, 8:00 AM EST - 4 months ago

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Dec 10, 2024, 8:00 AM EST - 4 months ago

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Nov 27, 2024, 8:00 AM EST - 4 months ago

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 13, 2024, 4:10 PM EST - 5 months ago

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 8:00 AM EST - 5 months ago

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Oct 30, 2024, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Oct 21, 2024, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 6 months ago

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Sep 30, 2024, 8:00 AM EDT - 6 months ago

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Sep 27, 2024, 8:00 AM EDT - 6 months ago

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Sep 19, 2024, 8:00 AM EDT - 6 months ago

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Aug 30, 2024, 8:00 AM EDT - 7 months ago

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Aug 29, 2024, 8:00 AM EDT - 7 months ago

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:10 PM EDT - 8 months ago

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 12, 2024, 4:00 PM EDT - 8 months ago

Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Aug 7, 2024, 8:00 AM EDT - 8 months ago

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

May 30, 2024, 8:00 AM EDT - 10 months ago

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

May 24, 2024, 8:00 AM EDT - 11 months ago

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

May 23, 2024, 8:00 AM EDT - 11 months ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

May 9, 2024, 4:10 PM EDT - 11 months ago

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 8, 2024, 8:00 AM EDT - 11 months ago

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Mar 25, 2024, 7:30 AM EDT - 1 year ago

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Mar 4, 2024, 4:10 PM EST - 1 year ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 20, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 6, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 9:08 AM EST - 1 year ago

Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering

Nov 27, 2023, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

Nov 21, 2023, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 1:45 PM EST - 1 year ago

Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 8:00 AM EST - 1 year ago

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 10, 2023, 8:00 AM EST - 1 year ago

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Nov 3, 2023, 8:10 AM EDT - 1 year ago

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

Oct 11, 2023, 7:14 PM EDT - 1 year ago

Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering

Oct 11, 2023, 5:10 PM EDT - 1 year ago

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Astria Therapeutics: Too Much Baggage, Too Strong A Competition

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Participate in Upcoming Investor Conferences

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

Aug 25, 2023, 8:00 AM EDT - 1 year ago

Market Cap	301.36M
Revenue (ttm)	0.00
Net Income (ttm)	-94.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	243,800
Avg Vol	263,010
Day's Range	N/A - N/A
Shares Out	56.43M
Stochastic %K	22%
Beta	0.69
Analysts	Strong Sell
Price Target	$26.50